Ono Pharmaceutical (TSE:4528) Is Down 7.0% After Gastric Cancer Drug ONO-4578 Advances To Phase 3 – Has The Bull Case Changed?

• In early June 2026, Ono Pharmaceutical reported phase 2 data showing its EP4 antagonist ONO-4578, combined with nivolumab and chemotherapy, improved progression-free survival and other efficacy measures versus placebo in previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer, without new safety concerns.
• The benefit was especially marked in patients with PD-L1 CPS ≥1, and Ono, together with affiliate Deciphera, now plans a pivotal phase 3 study to test ONO-4578’s potential to enhance current immunochemotherapy standards in this setting.
• We’ll now look at how the move toward a pivotal phase 3 program for ONO-4578 may influence Ono Pharmaceutical’s investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 27 companies in the world exploring or producing it. Find the list for free.

What Is Ono Pharmaceutical's Investment Narrative?

To own Ono Pharmaceutical, you really need to believe in its ability to replenish and extend its oncology franchise while managing a business that guidance already frames as relatively flat in the near term. The phase 2 win for EP4 antagonist ONO-4578 in first-line HER2-negative gastric cancer clearly adds a new talking point: it gives Ono and Deciphera a credible rationale to move into phase 3 and slightly strengthens the shorter term catalyst set, which had been more about steady Opdivo cash flows, the ripretinib filing in GIST and a dependable dividend. That said, the market’s recent pullback suggests investors are still focused on forecast revenue and earnings declines over the next few years and on execution risk in late-stage development, where disappointment can quickly reset expectations.

However, there is one clinical and revenue risk in particular that investors should not ignore. Despite retreating, Ono Pharmaceutical's shares might still be trading 34% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly ¥1,276 to about ¥3,352, underlining how differently private investors see Ono’s prospects as phase 3 execution, revenue pressure and oncology concentration all pull sentiment in opposing directions.

Explore 3 other fair value estimates on Ono Pharmaceutical - why the stock might be worth 43% less than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ono Pharmaceutical research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ono Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ono Pharmaceutical's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.